Literature DB >> 29531898

PACIFIC trial: new perspectives for immunotherapy in lung cancer.

Francesco Agustoni1, Fred R Hirsch1.   

Abstract

Entities:  

Year:  2018        PMID： 29531898      PMCID： PMC5835637          DOI： 10.21037/tlcr.2017.12.12

Source DB:  PubMed          Journal:  Transl Lung Cancer Res        ISSN： 2218-6751


× No keyword cloud information.
  17 in total

1.  Effect of host immune capability on radiocurability and subsequent transplantability of a murine fibrosarcoma.

Authors:  H B Stone; L J Peters; L Milas
Journal:  J Natl Cancer Inst       Date:  1979-11       Impact factor: 13.506

2.  Radiotherapy alone versus combined chemotherapy and radiotherapy in unresectable non-small cell lung carcinoma.

Authors:  T Le Chevalier; R Arriagada; E Quoix; P Ruffie; M Martin; J Y Douillard; M Tarayre; M J Lacombe-Terrier; A Laplanche
Journal:  Lung Cancer       Date:  1994-03       Impact factor: 5.705

3.  Identification and Characterization of MEDI4736, an Antagonistic Anti-PD-L1 Monoclonal Antibody.

Authors:  Ross Stewart; Michelle Morrow; Scott A Hammond; Kathy Mulgrew; Danielle Marcus; Edmund Poon; Amanda Watkins; Stefanie Mullins; Matthieu Chodorge; John Andrews; David Bannister; Emily Dick; Nicola Crawford; Julie Parmentier; Marat Alimzhanov; John S Babcook; Ian N Foltz; Andrew Buchanan; Vahe Bedian; Robert W Wilkinson; Matthew McCourt
Journal:  Cancer Immunol Res       Date:  2015-05-05       Impact factor: 11.151

4.  Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study.

Authors:  Scott Antonia; Sarah B Goldberg; Ani Balmanoukian; Jamie E Chaft; Rachel E Sanborn; Ashok Gupta; Rajesh Narwal; Keith Steele; Yu Gu; Joyson J Karakunnel; Naiyer A Rizvi
Journal:  Lancet Oncol       Date:  2016-02-06       Impact factor: 41.316

5.  Concurrent irradiation with the anti-programmed cell death ligand-1 immune checkpoint blocker durvalumab: Single centre subset analysis from a phase 1/2 trial.

Authors:  Antonin Levy; Christophe Massard; Jean-Charles Soria; Eric Deutsch
Journal:  Eur J Cancer       Date:  2016-10-17       Impact factor: 9.162

Review 6.  The synergistic effect of radiotherapy and immunotherapy: A promising but not simple partnership.

Authors:  Enrique Chajon; Joël Castelli; Hugo Marsiglia; Renaud De Crevoisier
Journal:  Crit Rev Oncol Hematol       Date:  2017-02-04       Impact factor: 6.312

7.  Local radiation therapy of B16 melanoma tumors increases the generation of tumor antigen-specific effector cells that traffic to the tumor.

Authors:  Amit A Lugade; James P Moran; Scott A Gerber; Robert C Rose; John G Frelinger; Edith M Lord
Journal:  J Immunol       Date:  2005-06-15       Impact factor: 5.422

8.  Safety and Efficacy of Durvalumab (MEDI4736), an Anti-Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer.

Authors:  Christophe Massard; Michael S Gordon; Sunil Sharma; Saeed Rafii; Zev A Wainberg; Jason Luke; Tyler J Curiel; Gerardo Colon-Otero; Omid Hamid; Rachel E Sanborn; Peter H O'Donnell; Alexandra Drakaki; Winston Tan; John F Kurland; Marlon C Rebelatto; Xiaoping Jin; John A Blake-Haskins; Ashok Gupta; Neil H Segal
Journal:  J Clin Oncol       Date:  2016-06-06       Impact factor: 44.544

9.  Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer.

Authors:  Scott J Antonia; Augusto Villegas; Davey Daniel; David Vicente; Shuji Murakami; Rina Hui; Takashi Yokoi; Alberto Chiappori; Ki H Lee; Maike de Wit; Byoung C Cho; Maryam Bourhaba; Xavier Quantin; Takaaki Tokito; Tarek Mekhail; David Planchard; Young-Chul Kim; Christos S Karapetis; Sandrine Hiret; Gyula Ostoros; Kaoru Kubota; Jhanelle E Gray; Luis Paz-Ares; Javier de Castro Carpeño; Catherine Wadsworth; Giovanni Melillo; Haiyi Jiang; Yifan Huang; Phillip A Dennis; Mustafa Özgüroğlu
Journal:  N Engl J Med       Date:  2017-09-08       Impact factor: 91.245

Review 10.  Development of PD-1/PD-L1 Pathway in Tumor Immune Microenvironment and Treatment for Non-Small Cell Lung Cancer.

Authors:  Jiabei He; Ying Hu; Mingming Hu; Baolan Li
Journal:  Sci Rep       Date:  2015-08-17       Impact factor: 4.379
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.